SLC22A5 and colonic neoplasm: Therefore, one of the potential pitfalls in the use of LC-PLGA NPs for drug delivery to treat colon cancer is the likely interaction of the drug-loaded NPs with OCTN2 in the small intestine prior to reaching the targeted site, namely the colon.